This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
AptarGroup, Inc. completed the acquisition of remaining 35.4% stake in Voluntis S.A.. CI
Global markets live: Intel, Apple, Rolls-Royce, Raytheon, MGM... Our Logo
Global markets live: Thales, Nestlé, Evergrande, AMC, Walmart... Our Logo
Global markets live: Amazon, Delivery Hero, Walmart, Broadcom, JD.com, Didi Global... Our Logo
AptarGroup : Completes Deal to Buy Nearly 65% of Voluntis; Mandatory Takeover Offer to Commence MT
AptarGroup : Completes Acquisition of Majority Stake in Voluntis MT
Voluntis S.A. Announces Executive Changes CI
AptarGroup, Inc. made an offer to acquire remaining 35.4% stake in Voluntis S.A. for €27.4 million. CI
AptarGroup, Inc. completed the acquisition of 64.6% stake in Voluntis S.A. from Vesalius Biocapital Partners S.à r.l, LBO France, Sham Innovation Santé, Bpifrance Participations SA, Debiopharm Innovation Fund SA and Eric Carreel. CI
AptarGroup : Signs Deal to Buy Majority Stake in Digital Therapeutics Firm Voluntis for 8.70 Euros Per Share MT
AptarGroup, Inc. signed a share purchase agreement to acquire 64.6% stake in Voluntis S.A. from Vesalius Biocapital Partners S.à r.l, LBO France, Sham Innovation Santé, Bpifrance Participations SA, Debiopharm Innovation Fund SA and Eric Carreel for €50.1 million. CI
Linklaters Advises Aptar on Entering into Exclusive Negotiations Regarding A Potential Acquisition of Voluntis CI
Voluntis Enters into Exclusive Negotiations with AptarGroup CI
AptarGroup : Says in Exclusive Negotiations on Potential Acquisition of Voluntis MT
Global markets live: Apple, Nvidia, Biogen, Fastly, Tilray... Our Logo
Global markets live: Uber, AB Inbev, PayPal... Our Logo
Global markets live: Tesla, UBS, Novartis... Our Logo
Voluntis and Eisai to Collaborate on Digital Therapeutics for Oncology Patients CI
Voluntis S.A. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Broward Health and Voluntis Launch A New Clinical Evaluation Program on Digital Therapeutics for Metastatic Breast Cancer CI
Voluntis : Changes Listing to Euronext Growth Paris From Euronext Paris MT
Voluntis S.A.(ENXTPA:ALVTX) dropped from CAC Small Index CI
Voluntis S.A.(ENXTPA:ALVTX) dropped from CAC All-Tradable Index CI
Voluntis : Rises 5% on Receipt of European Patent for Drug Dosing Support Technology MT
Voluntis : To Change Listing To Euronext Growth Paris; Shares Up 10% MT
Chart Voluntis S.A.
More charts
Voluntis SA is a France-based company specialized in medical solutions. The Company designs prescription applications that embed medical intelligence in the smart phones of people suffering from chronic and rare diseases. Voluntis SA develops digital solutions for diabetes, respiratory diseases, cancer, anticoagulation and hemophilia. Its product portfolio includes Insulia, a prescription-only medical device, which is a digital therapeutic for people with type 2 diabetes who are being treated with long-acting basal insulin. The medical device also provides patients with insulin dose recommendations and educational coaching messages based on blood glucose values and other diabetes-related data; Theraxium platform, which is a flexible platform that transforms health data into medical intelligence, and Quality and Regulatory Expertise, which focuses on patient safety, among others.
More about the company
  1. Stock Market
  2. Equities
  3. ALVTX Stock
  4. News Voluntis S.A.
  5. Voluntis : To Change Listing To Euronext Growth Paris; Shares Up 10%